Tirzepatide
Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Who's worth your money for Tirzepatide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 26 scored sellers
$1800 · 1200mg · 99.1% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 20mg · 99.8% purity
Most tested
57 independent COAs on file
$158 · 40mg · 99.9% purity
Average price
$4.03/mg
Sellers
48
45-day trend
-2.5%
42 of 48 sellers have a current price· 5 stale hidden· 11 unverified hidden
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · 1h ago
$1.50/mg -62.8% vs avg$1800
1200mg
- 🇺🇸 Hydro Research Peptides97
via Disclosed Labs · 1h ago
$4.65/mg +15.5% vs avg$465
100mg
- 🇺🇸 Prime Peptides96
via Disclosed Labs · 1h ago
$4.33/mg +7.6% vs avg$260
60mg
- 🇺🇸 Sunrise Bioresearch95
via Disclosed Labs · 1h ago
$0.60/mg -85.1% vs avg$359
600mg
- 🇺🇸 Reta One Labs95
via Disclosed Labs · 1h ago
$1.85/mg -54.1% vs avg$185
100mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 1h ago
$3.33/mg -17.2% vs avg$200
60mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 1h ago
$3.95/mg -1.9% vs avg$158
40mg
- 🇺🇸 Forge Performance Co.94
via Disclosed Labs · 1h ago
$3.33/mg -17.2% vs avg$100
30mg
- Nova Peptides94
via Disclosed Labs · 1h ago
$3.50/mg -13.1% vs avg$350
100mg
no purity - 🇺🇸 Ignite Peptides93
via Disclosed Labs · 1h ago
$5.00/mg +24.2% vs avg$150
30mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Tirzepatide
Get one email when the market actually moves — no newsletter, no noise.
About Tirzepatide
CAS
2023788-19-2
Molecular formula
C225H348N48O68
Sequence
YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSamide
Typical dose range
2.5–15 mg once weekly subcutaneous injection (research studies mirror clinical titration: start 2.5 mg/week, escalate by 2.5 mg every 4 weeks to max 15 mg/week)
Half-life
~5 days (~120 hours)
COAs for Tirzepatide
478 third-party tests across 56 vendors. Each card links to the full report.
For
Tirzeppatide
by Reta One Labs· batch TZ201026
For
Tirzepatide
by NG Peptide· batch TRZ60-05
For
Tirzepatide
by VoriLabs· batch TR60-2608-B
For
Tirzepatide
by VoriLabs· batch TR60-2608-A
For
Tirzepatide
by Sunrise Bioresearch· batch GLP230JUL26-01
For
Tirzepatide
by Novaglo Research· batch 5001072226TZ
For
Tirzepatide
by Novaglo Research· batch 5001572326TZ
For
Tirzepatide
by Novaglo Research· batch 5000572226TZ
For
Tirzepatide
by NovaForge Labs· batch LOT-TR-QSCT1
For
Tirzepatide
by Velora Biolabs· batch VBL-TR10-1
For
Tirzepatide
by Velora Biolabs· batch VBL-TR30-1
For
Tirzepatide
by Velora Biolabs· batch VBL-TR60-1
For
Tirzepatide
by Novaglo Research· batch 5003071726TZ
For
Tirzepatide
by VoriLabs· batch VoriLabs TR60-2607-F
For
Tirzepatide
by VoriLabs· batch VoriLabs TR60-2607-D
For
Tirzepatide
by VoriLabs· batch VoriLabs TR60-2607-C
For
Tirzepatide
by Crush Research· batch CR-2XAG-60-2607-Purple
For
Tirzepatide
by jdbioworks· batch 2026-002
For
Tirzepatide
by Artisan Aminos· batch AA-TRZ220-049
For
Tirzeptide
by Ignite Peptides· batch IP-2607-127
For
Tirzepatide
by Ignite Peptides· batch IP-2607-797
For
Tirzepatide
by Certified Peptides· batch TIR070226
For
Tirzepatide
by VoriLabs· batch TR60-2606-A
For
Tirzepatide
by NG Peptide· batch TRZ40-15
23 citations indexed for Tirzepatide
cohort · 2026
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness.
animal · 2026
Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling
Metabolic stress, hepatic lipid accumulation, and macrophage-associated sterile inflammation are closely involved in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Tirzepatide improves metabolic outcomes, but its effects on macrophage inflammatory signaling in MASLD remain unclear.
Study · 2026
Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort
Objective To assess early renal and lithium-related safety and 12-month renal biomarker trajectories after tirzepatide initiation in lithium-treated adults with bipolar disorder. Methods We retrospectively studied 23 adults at one centre.
Study · 2026
Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues
Objective As obesity and diabetes are on the verge of an alarming growth, so is the use of tirzepatide, a novel dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 (GLP-1) receptor agonist (RA) and currently the most effective weight loss-drug.
Study · 2026
Tirzepatide use in adolescents with metabolic dysfunction‐associated steatotic liver disease (MASLD): A case series
meta-analysis · 2026
Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies
This systematic review and meta-analysis aimed to compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity. We included randomised controlled trials and observational studies comparing tirzepatide and semaglutide with ≥ 24 weeks of follow-up.